Studies have supported the neuroprotective effects of fingolimod in multiple sclerosis, which are mediated through downregulation of IL-17 signaling and inhibition of NF-κB translocation and NO production in astrocytes [48,49,50]. The gene discussed is IL17A; the disease is multiple sclerosis.